KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$2.4 billion.

  • Ionis Pharmaceuticals' Retained Earnings fell 1194.81% to -$2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 billion, marking a year-over-year decrease of 1194.81%. This contributed to the annual value of -$2.2 billion for FY2024, which is 2527.39% down from last year.
  • Ionis Pharmaceuticals' Retained Earnings amounted to -$2.4 billion in Q3 2025, which was down 1194.81% from -$2.3 billion recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Retained Earnings peaked at -$1.2 billion during Q4 2021, and registered a low of -$2.4 billion during Q3 2025.
  • For the 5-year period, Ionis Pharmaceuticals' Retained Earnings averaged around -$1.7 billion, with its median value being -$1.6 billion (2023).
  • Per our database at Business Quant, Ionis Pharmaceuticals' Retained Earnings plummeted by 5229.56% in 2021 and then soared by 52.88% in 2022.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Retained Earnings stood at -$1.2 billion in 2021, then fell by 23.25% to -$1.4 billion in 2022, then decreased by 25.62% to -$1.8 billion in 2023, then dropped by 25.27% to -$2.2 billion in 2024, then dropped by 6.76% to -$2.4 billion in 2025.
  • Its Retained Earnings was -$2.4 billion in Q3 2025, compared to -$2.3 billion in Q2 2025 and -$2.4 billion in Q1 2025.